Skip to main content
. 2024 May 22;10(11):e31695. doi: 10.1016/j.heliyon.2024.e31695

Table 1.

Correlation between P4HA3 expression and clinicopathological parameters.

Characteristic P4HA3low P4HA3high P value
N 131 49
Gender, n (%) 0.642
 Male 80 (71.4 %) 32 (28.6 %)
 Female 50 (74.6 %) 17 (25.4 %)
Age (years), n (%) 0.019
 ≤65 75 (80.6 %) 18 (19.4 %)
 >65 56 (65.1 %) 30 (34.9 %)
T-stage, n (%) 0.008
 T1 8 (100 %) 0 (0 %)
 T2 27 (90 %) 3 (10 %)
 T3 76 (71.7 %) 30 (28.3 %)
 T4 20 (57.1 %) 15 (42.9 %)
N-stage, n (%) < 0.001
 N0 76 (80.9 %) 18 (19.1 %)
 N1 37 (78.7 %) 10 (21.3 %)
 N2 18 (47.4 %) 20 (52.6 %)
M-stage, n (%) 0.235
 M0 129 (74.1 %) 45 (25.9 %)
 M1 2 (40 %) 3 (60 %)
Pathologic stage, n (%) 0.018
 stageⅠ 7 (100 %) 0 (0 %)
 stage Ⅱ 69 (80.2 %) 17 (19.8 %)
 stage Ⅲ 53 (65.4 %) 28 (34.6 %)
 stage Ⅳ 2 (40 %) 3 (60 %)
Tumor site, n (%) 0.394
 Rectum 65 (75.6 %) 21 (24.4 %)
 Colon 65 (69.9 %) 28 (30.1 %)
Histological type, n (%) 0.221
 Adenocarcinoma 123 (71.5 %) 49 (28.5 %)
 Mucinous adenocarcinoma 7 (100 %) 0 (0 %)
Degree of differentiation, n (%) 0.040
 Moderately differentiated 120 (76.9 %) 36 (23.1 %)
 Poorly differentiated 8 (50 %) 8 (50 %)
Vascular recidivism, n (%) 0.356
 No 116 (74.4 %) 40 (25.6 %)
 Yes 15 (65.2 %) 8 (34.8 %)
Lymphatic recidivism, n (%) 0.013
 No 101 (78.3 %) 28 (21.7 %)
 Yes 30 (60 %) 20 (40 %)
Neurorecidivism, n (%) 0.134
 No 121 (75.2 %) 40 (24.8 %)
 Yes 10 (55.6 %) 8 (44.4 %)